📇 Rhumatologue · NANCY CEDEX · (54) · Hospitalier

MME LUCIE HOPES

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
23 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
146.3 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 NANCY CEDEX (54)HospitalierRPPS 10100555894

Publications actives

26 publications sur 5 ans↗

📊 Reconnaissance scientifique : 10/100📝 46 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Targeting chelatable iron as a therapeutic modality in Parkinson's disease

Antioxidants & redox signaling · 2014

📚 503 citations🎯 RCR 18.05Top 1% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments. Results: For translational studies, we assessed the effect of oxidative insults in mice systemically prechelated with deferiprone (DFP) by following motor functions, striatal dopamine (HPLC and MRI-PET), and brain iron deposition (relaxation-R2*-MRI) aided by spectroscopic measurements of neuronal labile iron (with fluorescence-sensitive iron sensors) and oxidative damage by markers of protein, lipid, and DNA modification. DFP significantly reduced labile iron and biological damage in oxidation-stressed cells and animals, improving motor functions while raising striatal dopamine. For a pilot, double-blind, placebo-controlled randomized clinical trial, early-stage Parkinson's patients on stabilized dopamine regimens enrolled in a 12-month single-center study with DFP (30 mg/kg/day). Based on a 6-month DS paradigm, early-start patients ( n =19) compared to DS patients ( n =18) (37/40 completed) responded significantly earlier and sustainably to treatment in both substantia nigra iron deposits (R2* MRI) and Unified Parkinson's Disease Rating Scale motor indicators of disease progression ( p <0.03 and p <0.04, respectively). Apart from three rapidly resolved neutropenia cases, safety was maintained throughout the trial. Innovation: A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD. Conclusions: The therapeutic features of a chelation modality established in translational models and in pilot clinical trials warrant comprehensive evaluation of symptomatic and/or disease-modifying potential of chelation in PD. Antioxid. Redox Signal . 21, 195–210.

Trial of Lixisenatide in Early Parkinson's Disease

The New England journal of medicine · 2024

📚 240 citations🎯 RCR 51.30Top 0% NIH🩺 Clinique

Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study

Neurology · 2022

📚 119 citations🎯 RCR 12.33Top 2% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME LUCIE HOPES

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (23) — classées par pathologie

Transversal18

Santé mentale / fatigue2

Épidémiologie & registres1

Génétique1

IRM ostéo-articulaire1

Datasets & protocoles partagés

Partager cette fiche